We have all heard about the recent 100% pharma tariff announcement, applicable mainly to manufacturers or marketed drugs unless they are in the process of building manufacturing facilities in the US. We know that early stage biotechs are generally not counting on investment to take them through manufacturing, for which they will seek a pharma partner. Nevertheless, these tariffs may still have an effect on early-stage biotech investments. Investment in early-stage (seed, Series A/B) biotech is likely to face increased headwinds under a 100 % pharmaceutical tariff regime. The tariff risk exacerbates existing structural challenges in biotech investing.
Overall Expected Effect (Short to Medium Term)
Slower fundraising pace
The number of deals may decline, particularly in the earlier stages. Biotech investors will likely become more selective, preferring de-risked assets, strong data, or compelling platforms with clear strategies to mitigate tariff exposure.
Higher effective cost of capital
Investors will demand more upside or stricter protections (e.g. liquidation preferences, anti-dilution) to compensate for the added risk.
Greater emphasis on capital efficiency / leaner burn models
Startups may need to conserve cash more, focus earlier on key inflection points, outsource less, and plan fallback strategies for supply chain risk.
Longer timelines / delayed exits
Because of the risk, uncertainty, and possible delays, the time to IPO, acquisition, or commercialization may stretch, further compressing IRR for investors.
Capital flow shift toward infrastructure and enabling technologies
Some portion of venture capital may redirect toward bioprocessing, domestic manufacturing, synthetic biology for local API production, supply-chain tools — companies that can help others evade tariff impact.
Public market investment in pharma may slow, leading to less IPOs
The tariffs could serve to further erode the attractiveness of the biopharma sector for public market investors, reducing the room for IPOs, and pressuring investment taking place more upstream.
In summary, while the recent 100% pharma tariffs certainly don’t have a direct effect on early-stage biotech investing, their dampening effects will nonetheless be felt.
Commercial interest in targeted epigenetic therapies — agents that target specific genes without altering bases in their sequence or causing double-strand breaks or even single nicks in the DNA — continues to grow, as underscored by the latest financing announced by Epigenic Therapies. The unique selectivity and specificity of targeted epigenetic therapeutics offers compelling advantages over small-molecule epigenetic drugs, which target a specific epigenetic reader, writer or eraser, but affect genes across the genome and affect many diverse tissues, leading to narrow therapeutic windows that make them difficult to develop for conditions outside of cancer.
All of these therapies are designed around an alluring set of simple principles: take a gene-specific DNA-binding domain — zinc-finger proteins (ZFPs), ‘dead’ Cas9 (dCas9) with mutations in its RuvC and HNH endonuclease domains, or transcription activator-like effectors (TALEs) — and tether it via an amino acid linker to an enzymatic effector module. This effector is either an enzyme that directly places or removes a specific epigenetic modification (e.g., TET, histone demethylases or the histone acetyltransferase p300) or a transcriptional activator (e.g., VP16) or repressor (e.g., KRAB).
Epigenetic editing approaches have recently focused on dead CRISPR (dCRISPR) domains fused to various epigenetic effectors, but transcription activator-like effectors (TALEs) and zinc finger proteins (ZFPs) also continue to be explored. Source: TINS
A particularly compelling application for such treatments is genetic disorders of haploinsufficiency (like Dravet’s) or imprinting disorders (like Angelman’s or Prader Willi). There are also many of these diseases where the therapeutic genes would be too large (>4.0 kb) for a traditional AAV gene-therapy approach; in contrast, epigenetic editing machinery can be packaged into an AAV vector.
In a first paper published in Nature, the groups of Kevin Bender and Nadav Ahituv at UCSF (scientific co-founders of Regel Therapeutics) sought to test a targeted epigenetic therapy in patients with SCN2A mutations that exhibit decreased NaV1.2 function. These individuals have impaired action potentials, synaptic transmission and manifest diverse neurological symptoms and seizures, with few therapeutic options, beyond symptomatic anti-seizure medications that have a dizzying range of debilitating side effects.
The UCSF teams leveraged conditional genetic knock-in technolgoy or CRISPRa technology — an AAV-delivered SCN2A-promoter-targeting dCas9 fused to a VP16 activator domain — to upregulate transcription of the SCN2A gene. Using either approach, they were able to boost transcript levels from the healthy SCN2A allele, ameliorating electrophsiological deficits and chemical-induced seizure activity in Scn2a+/− mouse models. Importantly, these effects were seen in adolescent mice, which conventionally have been thought to be too old to respond to treatment. This suggests that rescue of normal dendritic excitability with epigenetic agents at later stages of life might be capable of restoring neuronal function, with implications for patients.
In a separate set of experiments, the authors showed that their epigenetic approach was able to rescue neurophysiological activity in haploinsufficient neuron-like cells from SCN2A-knockout human embryonic stem cells. This cross-species reproducibility provides further confidence that CRISPRa-mediated upregulation could be translated into human treatments.
In a second paper in Nature Biotechnology, a team from Epigenic Therapeutics (Shanghai, China) describes the design and validation of optimized epigenetic regulators (EpiRegs) to silence genes in a precise, durable way without altering genomic DNA. Epigen’s Shaoshai Mao and his collaborators at the Chinese Academy of Sciences and the First Affiliated Hospital of Anhui Medical University tested combinations of TALE- and dCas9-based systems, systematically optimizing effector domains and fusion architectures, looking for effective regulators of gene expression. The best-performing variant, EpiReg-T (a TALE-based system, which eliminates the need for a guide RNA), achieved 98% silencing of target genes in mice, substantially outperforming dCas9-based versions.
Using lipid nanoparticles (LNPs) for delivery, a single administration of EpiReg-T in macaques induced long-term repression of the PCSK9 gene, which encodes a validated target for the treatment of hypercholesterolemia. EpiReg-T reduced PCSK9 expression by >90% and LDL-cholesterol by about 60%, with effects persisting for nearly a year (343 days).
Mechanistically, the team used whole-genome bisulfite sequencing and cleavage under targets and tagmentation (CUT&Tag) to show that EpiReg-T induced stable DNA methylation and repressive histone marks at the PCSK9 promoter. The silencing persisted even after liver regeneration and could be reversed by targeted epigenetic activation. Multiomic analysis in mice, macaques and human hepatocytes confirmed high specificity of the manipulation and minimal off-target effects. Overall, these finding, as well as similar results reported in April by Chroma Medicine, establish epigenetic editing as a promising therapeutic platform for durable and reversible gene silencing.
Overall, targeted epigenetic therapies offer clear safety advantages over small molecules that indiscriminately target all genes under the control of an epigenetic eraser or writer enzymes. They avoid the potential risks associated with creating single- or double-strand DNA breaks associated with CRISPR/Cas9 gene, base or prime editing therapies. And they avoid the insertional mutagenesis risks associated with traditional viral gene therapies. What’s more, in applications requiring gene upregulation in haploinsufficient disease, these approaches maintain the endogenous regulatory context of the functional allele. This is in stark contrast to traditional gene-therapy replacement approaches, where overexpression of an introduced therapeutic gene can often lead to toxicities and immunogenecity.
Of course, questions still linger around the persistence of the changes elicited by these epigenetic agents. Will they persist in patients for long periods — for years or even decades? If they can, then epigenetic therapy may offer compliance advantages over small molecules, antibodies, ASOs or even siRNAs, which have treatment durations of six months or less.
Like all genetic medicines, though, delivery remains the key headache. Thus far, AAV vectors, lipid nanoparticles or ribonucleoproteins (RNP) have all been explored to deliver epigenetic therapies (with some evidence that RNPs might have advantages because they can result in higher dCas9 dosages within target cells). For AAV vectors, the fact that targeted epigenetic therapy might only need to be given once might be an advantage in terms of immunogenicity/neutralization concerns against the vector.
A broader point is that the safety profile of targeted epigenetic editors may offer advantages if AAV vectors are used as delivery vehicles: if the epigenetic agents themselves can be delivered at high dosage (given their intrinsic favorable safety profile and presumed maximal tolerated dose), perhaps AAV vector dosages could be lower than current practice. With many current gene therapies requiring dosages of 1013 or more viral particles/kg in patients, it is increasingly becoming clear that unacceptable liver toxicities arise from the virus at these levels in clinical studies. It will be interesting to follow this space as more agents enter human testing.
Life Science Nation’s Redefining Every Stage of Investments (RESI) conferences are designed to connect life science companies with global investors and strategic partners. Two major upcoming events, RESI London and RESI JPM, are now open for registration at Super Early Bird rates through October 3. By registering early, attendees can save £300 on RESI London and $800 on RESI JPM.
RESI London 2025
The first week of December marks the largest life science partnering and venture week in the UK. If you are raising pre-seed, seed, round A or round B, or are in phase 2 or earlier development, Life Science Nation’s RESI London, One Nucleus’ Genesis, and ELRIG/SLAS events offer stronger partnering, investment, learning, and procurement opportunities compared to the health care week in late November that runs alongside the Jefferies investment banking event. That November week typically focuses on recent IPOs, companies close to IPO, and phase 3 or more advanced companies seeking partnerships. For companies not yet at that stage, December’s conference series is a more strategic use of critical conference and travel budgets.
RESI London and Genesis are joining to provide a multi-day investment, partnering, and thought leadership event for venture-stage companies pursuing funding and strategic alliances. RESI London will take place on December 4 at 1 Wimpole Street and 11 Cavendish Square, followed by two days of virtual partnering on December 5 and 6. Super Early Bird registration is now open, offering a savings of £300 until October 3.
RESI JPM 2026
RESI JPM will be held January 12–13, 2026, at the San Francisco Marriott Marquis. The program features two days of in-person investor panels, workshops, networking, and one-on-one partnering, followed by three days of online partnering on January 14, 19, and 20.
Previous RESI JPM conferences have drawn more than one thousand attendees, including over 500 investors, innovators, and industry experts from across the globe. The conference is held concurrently with JP Morgan Healthcare Week, January 12–15, 2026, which takes place at the Westin St. Francis. Known as the largest healthcare investment symposium worldwide, JPM attracts thousands of life science professionals each year.
Super Early Bird registration for RESI JPM offers a savings of $800 when completed before October 3.
Both conferences provide access to global investors and in-licensors, strategic partners, and hundreds of early-stage innovators across therapeutics, medical devices, diagnostics, and digital health. Register now to take advantage of Super Early Bird discounts for RESI London and RESI JPM before October 3.
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
Life Science Nation (LSN) is excited to announce the lineup of investor panels at RESI JPM 2026, taking place January 12–13. These panels bring together leading venture capitalists, corporate investors, and strategic partners to discuss the latest trends, challenges, and opportunities in life science investing. From early-stage “first check” VCs to specialized sectors like Cell & Gene Therapy, AI in Healthcare, and Longevity, RESI JPM offers unparalleled insight into the funding landscape.
Day 1 – January 12
9:00 AM | “First Check” VCs Panel: Learn how early-stage investors evaluate founders, milestones, and the critical first institutional check.
10:00 AM | Medtech Strategics Panel: Explore how strategic investors from leading medtech companies drive growth through partnerships and acquisitions.
11:00 AM | Asia Cross Border Investments Panel: Sponsored by Enterprise Singapore, a RESI JPM Title Sponsor
1:00 PM | Family Offices Panel: Hear how family offices provide patient, mission-driven capital to early- and growth-stage companies.
2:00 PM | Cell & Gene Therapy Panel: Discover where capital is flowing in this transformative area of medicine.
3:00 PM | When Should Companies Exit Stealth Mode?: Gain insight into timing the transition from quiet development to public visibility.
4:00 PM | Aging and Longevity Panel: Learn how investors are deploying capital to solutions addressing the world’s aging population.
Day 2 – January 13
9:00 AM | Partnering with Global Pharma Panel: Understand how big pharma approaches early-stage partnerships and collaboration.
10:00 AM | Women’s Health Panel: Explore investment opportunities in an underserved market with enormous potential.
11:00 AM | AI in Healthcare: Discover how AI is reshaping drug development and care delivery.
1:00 PM | Orphan & Rare Diseases Panel: Learn about unique challenges and opportunities in niche, high-need markets.
2:00 PM | Corporate VC Panel: Hear how corporate venture capital balances strategic and financial goals to accelerate innovation.
3:00 PM | Techbio & Synthetic Biology Panel: Explore investment trends at the intersection of biology and technology.
4:00 PM | 2026 Outlook: VC Perspectives Panel: Gain insight into where investors see healthcare innovation heading in the coming year.
These panels are designed not only to share insights but also to foster dialogue between investors and innovators. If you are interested in speaking on a RESI JPM investor panel, please reach out here.
Registration for RESI JPM 2026 is now open, with Early Bird rates available until October 24. Don’t miss your chance to connect with top investors, strategic partners, and fellow innovators at one of the premier life science partnering events. Register for RESI JPM 2026
By Max Braht, Director of Business Development, LSN
Life Science Nation is on the move. Between now and RESI London, our team will be attending a series of leading life science and medtech conferences around the world, connecting with innovators, investors, and strategic partners. Getting out into the global ecosystem allows us to better understand emerging trends, foster collaborations, and support life science companies in reaching their fundraising and partnership goals.
These engagements also reinforce the value of our global conference, RESI, which brings together investors, entrepreneurs, and strategic partners from across the world to drive innovation in life sciences. Attending regional and international events helps us strengthen these connections and grow our global community.
Here’s where you can find our team in the coming months:
October
Oct. 4–8: San Diego for the MedTech conference, engaging with medical device innovators and investors.
San Diego, CA
Max Braht (m.braht@lifesciencenation.com)
Matt Stanton (m.stanton@lifesciencenation.com)
Oct. 4–8: LSN Bootcamp and BioSpain, connecting with early-stage life science companies.
Barcelona, Spain
Greg Mannix (g.mannix@lifesciencenation.com)
Karen Deyo (k.deyo@lifesciencenation.com)
Brenda Olmos (b.olmos@lifesciencenation.com)
Oct. 8–10: Japan for BioJapan, focusing on international biotech partnerships.
Yokohama, Japan
Dennis Ford (dford@lifesciencenation.com)
Claire Jeong (c.jeong@lifesciencenation.com)
Momo Yamamoto (m.yamamoto@lifesciencenation.com)
Oct. 21-23: Sao Paulo for Corporate Venture in Brazil 2025, highlighting innovation and investment opportunities in Latin America.
Sao Paulo, Brazil
Dennis Ford (dford@lifesciencenation.com)
Max Braht (m.braht@lifesciencenation.com)
Matt Stanton (m.stanton@lifesciencenation.com)
Oct 24-25: Washington DC for the 9th Annual KAPAL Conference, meeting global leaders in biotech and healthcare.
Washington DC
Sougato Das (s.das@lifesciencenation.com)
Oct. 27–28: Miami for the BioHunt Summit, meeting emerging life science startups and investors.
Miami, FL
Dennis Ford (dford@lifesciencenation.com)
Matt Stanton (m.stanton@lifesciencenation.com)
November
Nov. 2–6: Vienna for BioEurope, connecting with corporate and venture partners across the life science ecosystem.
Vienna, Austria
Max Braht (m.braht@lifesciencenation.com)
Greg Mannix (g.mannix@lifesciencenation.com)
Nov. 12–14: Malta at the MedTech World Summit, exploring opportunities in medical technology.
Valletta, Malta
Greg Mannix (g.mannix@lifesciencenation.com)
Brenda Olmos (b.olmos@lifesciencenation.com)
Nov. 16–20: London for Jefferies London Life Sciences Week, engaging with global investors and biotech innovators.
London, UK
Max Braht (m.braht@lifesciencenation.com)
Greg Mannix (g.mannix@lifesciencenation.com)
December
Dec. 2: France for Biofit/Medfit, meeting early-stage innovators and strategic partners in biotech and medtech.
Strasbourg, France
Max Braht (m.braht@lifesciencenation.com)
Matt Stanton (m.stanton@lifesciencenation.com)
We look forward to seeing our community at these events. If you’d like to connect with us while we’re on the road, please reach out to resi@lifesciencenation.com
In this interview, Caitlin Dolegowski speaks with Cuong Do, Founder and Chairman of M6P Therapeutics, about the company’s groundbreaking lysosomal targeting platform, its applications in rare disease and oncology, and the experience of pitching at RESI Boston.
Caitlin Dolegowski (CD): M6P Therapeutics has achieved what was long thought impossible, delivering proteins to lysosomes. Can you explain the significance of this breakthrough?
Cuong Do (DO): An enzyme called GlcNac-1-phosphotransferase (PTase) is responsible for adding mannose 6-phosphate to the surface of lysosomal enzymes. People have tried and failed for decades to increase the expression of M6P, and everybody gave up. Our co-founder Stuart Kornfeld never gave up. He and his post-doc were able to engineer a variant of PTase that turned out to be 20X more effective than PTase itself in adding M6P to lysosomal enzymes. We built upon this breakthrough to create a platform that is able to create enzyme replacement therapies that have very high M6P content. Furthermore, our gene therapies are the only ones that result in M6P-containing enzymes being produced by the transduced cells.
We expanded upon the innovation and created chimeric antibodies that contain M6P as well. This allows these antibodies (after they bind to the targeted antigens) to be brought to lysosomes in virtually all cells in our bodies for degradation. This is a significant advantage over traditional antibodies relying on Fc clearance by only select immune cells.
CD: You have multiple rare pediatric drug designations and two programs nearing the clinic. What are the most exciting upcoming milestones for your pipeline?
DO: We are preparing to start an Investigator Initiated Trial in Australia for our M021 ERT for Pompe Disease in hopes of obtaining early human data demonstrating M021’s superiority over the standard of care.
CD: How does your lysosomal targeting platform extend beyond rare diseases, particularly in oncology with your chimeric PD-L1 and PD-1 antibodies?
DO: We figured out a way to add M6P to any protein, including antibodies. Our chimeric antibodies can be cleared by virtually all cells in the body since virtually all cells have receptors for M6P. This is especially effective for clearing surface antigens from cell surfaces. Our chimeric PD-L1 antibody is able to clear virtually all PD-L1 from the surface of tumor cells and thus activate T-cells and drive T-cell mediated tumor killing. Our chimeric version of Keytruda is able to remove PD-1 from the surface of T-cells and has shown to be more effective in inhibiting tumor growth in vivo than Keytruda itself.
CD: Can you walk us through your IP position and how it supports your growth strategy?
DO: We have invested heavily in IP that has created a portfolio of 9 patent families, 9 issued patents, and ~20 still in prosecution.
CD: Where are you in your fundraising journey, and what types of investors or partners are you looking to engage with?
DO: We have raised ~$40 million in our Seed and A rounds, which we invested to get our programs to where they are today. We are trying to raise a $5 million bridge now in anticipation of a $50+ million Series B next year. In addition to investors, we want to engage with potential partners who might be interested in our molecules.
CD: How did participating in the Innovator’s Pitch Challenge at RESI Boston help advance your business development or investor connections?
DO: We met a few companies who might be interested in partnering on some of our molecules. We’re continuing the conversations.
IPC Applications are now open for the next Innovator’s Pitch Challenge at RESI London 2025 and RESI JPM 2026, with spots filled on a rolling basis.
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
At RESI Boston September 2025, over 50 innovative companies participated in the Innovator’s Pitch Challenge (IPC), providing early-stage life science and healthcare companies with a unique platform to present their technologies and connect with potential investors.
The IPC finalists delivered 6-minute pitches followed by a 7-minute interactive Q&A session with a panel of investor judges. Each participating company also showcased its technology at a personalized table space in the RESI Exhibition Hall, creating additional opportunities for engagement.
A distinctive feature of the Innovator’s Pitch Challenge is its voting system. Registered RESI attendees—including startup executives, early-stage investors, and industry experts— “invested” in their favorite IPC companies using RESI cash provided at check-in. Attendees base their decisions on both the pitch presentations, the companies’ responses during Q&A, meeting with them in the exhibition hall at their table space, and during partnering or ad-hoc meetings at RESI.
Applications are now open for the next Innovator’s Pitch Challenge at RESI London 2025 and RESI JPM 2026, with spots filled on a rolling basis.
IsoTech Ltd is developing a novel wearable therapeutic medical device that stabilises blood pressure on standing to help older adults avoid dizziness and falls from orthostatic hypotension. The device guides a 30–60-second, on-demand isometric muscle contraction via a discreet retractable tether with visual and haptic cues, turning an evidence-based counter-manoeuvre into a simple, repeatable action without drug side effects. A completed proof-of-concept clinical study demonstrated clinically meaningful blood-pressure stabilisation in a substantial subset of patients with high usability and no unwanted adverse effects. The next phase is straightforward but execution-critical: design-for-manufacture and verification, Class I UKCA/CE technical documentation and light-touch QMS, tooling and pilot build, and a KOL-led seeded launch while preparing reimbursement pilots and strategic licensing options. Protected by patents on mechanism and form factor, ISO-101 aims to become the category-defining, real-time therapy for OH, improving independence for ageing populations and reducing falls-related costs for health systems at scale.
Dr Lochlainn Connolly, Founder – EVP Medical Affairs, Isotech | Dr Neil Fawkes, Founder / EVP R&D, Isotech | Dennis Ford, Founder and CEO, Life Science Nation | Iggy McGowan, Founder / CEO, Isotech
Bilix, founded in Oct 2018, raised $21 million in investments and received $3 million in government grants to develop a new drug for various inflammatory and autoimmune diseases. Our first target is ischemia-reperfusion injury, where unmet medical needs are high and no drugs. Global companies (Novartis, Roche, AstraZeneca, Argenx) are in Phase 2 or 3 trials with single-modality drugs (likely to fail). Our Phase 2a clinical trial (our drug being multi-modality, likely to succeed) runs from 2025.09 to 2026.08. We generate royalty revenue from Classys (a $3B market cap laser medical device company) through exclusive LO in cosmeceutical products. We are currently raising Series B-3 of $6M, of which $ 3 M has been secured. With $25.7 million pre-money valuation, an ROI of >10 times is achievable within three years through IPO/M&A. We can flip to a US company with vetted Series C investments from US/Foreign VCs.
Dennis Ford, Founder and CEO, Life Science Nation | Myung L. Kim, Ph.D., MBA, Founder and Chief Executive Officer, Bilix | Claire Jeong, CCO, VP of Investor Research, Asia BD, Life Science Nation
M6P Therapeutics focuses on lysosomes (the natural recycling center for cells) and has the only technology that can deliver any protein to lysosomes – a feat deemed impossible for over 50 years. The company has a deep pipeline, 6 rare pediatric drug designations, and an IP portfolio comprised of 9 patent families, 8 issued patents, and 20 in progress. Our Gaucher Disease ERT is ready for the clinic and our Pompe Disease ERT – which can restore and normalize muscle function – will be ready in 18 months. We also created a platform that can take any antigen-antibody complex to the lysosomes of any cell in the body (instead of relying on Fc clearance by select immune cells) for degradation. Our “chimeric” anti-PD-L1 antibody removes virtually all PD-L1 from the surface of tumor cells while our chimeric version of Keytruda is twice as potent.
Cole Van Vuren, Business Development Manager, Life Science Nation
The participating companies were grouped into 14 sector-focused sessions, with four companies per session. Each session was evaluated by a panel of judges, and the top-scoring companies were recognized for their strong pitches, ability to answer questions effectively, and clear communication of their value propositions.
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
Cuong Do
Dr Lochlainn Connolly, Founder – EVP Medical Affairs, Isotech | Dr Neil Fawkes, Founder / EVP R&D, Isotech | Dennis Ford, Founder and CEO, Life Science Nation | Iggy McGowan, Founder / CEO, Isotech
Dennis Ford, Founder and CEO, Life Science Nation | Myung L. Kim, Ph.D., MBA, Founder and Chief Executive Officer, Bilix | Claire Jeong, CCO, VP of Investor Research, Asia BD, Life Science Nation
Cole Van Vuren, Business Development Manager, Life Science Nation
Next Phase Newsletter 